Skip to main content
Top
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer’s patients in long-term care health facilities

Authors: Kenichi Meguro, Yoshitaka Ouchi, Kyoko Akanuma, Mitsue Meguro, Mari Kasai

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

Cholinesterase inhibitors can delay the progression of Alzheimer’s disease (AD). Several clinical trials of the drug in moderate to severe AD have consistently reported clinically positive effects. A combining effect with psychosocial intervention was reported in mild to moderate AD patients. Since a therapeutic approach or rehabilitation combined with cholinesterase inhibitors for severe AD patients remains controversial, we performed a prospective intervention for patients in Long-Term Care Health Facilities (LTCHF).

Methods

Two LTCHFs (N1, N2) were enrolled. N1 is a 126-bed facility that does not treat with donepezil but rather with psychosocial intervention (reality orientation and reminiscence). N2 is a 150-bed facility with a 50-bed special dementia unit, in which the physician can prescribe donepezil. On top of the similar psychosocial intervention, rehabilitation is performed in N2. Thirty-two severe AD patients (MMSE < 6) in N1 and N2 (16 vs. 16) were compared for the effect of donepezil (10 mg/d for 3 months) with or without psychosocial intervention (n = 8 vs. 8 for each facility). The Vitality Index was used to assess daily activities and the introduction of rehabilitation.

Results

The response ratio (MMSE 3+) of donepezil was 37.5% in N2. The combination of donepezil with the psychosocial intervention improved the Vitality Index total score, and Communication, Eating, and Rehabilitation subscores (Wilcoxon, p = 0.016, 0.038, 0.023, and 0.011, respectively). Most of them were smoothly introduced to rehabilitation, and the proportion of accidental falls decreased. Psychosocial intervention in N1 without the drug only improved the total score (Wilcoxon, p = 0.046).

Conclusions

A combined therapeutic approach of donepezil and psychosocial intervention can have a positive effect, even for severe patients through the introduction of rehabilitation and decreasing accidental falls. However, these findings require replication in a larger cohort.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD, “312” Study Group: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001, 57:481–488., Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD, “312” Study Group: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001, 57:481–488.,
2.
go back to reference Gauthier S, Lopez OL, Waldermar G, Jones RW, Cummings J, Zhang R, Schindler R, Schwam E: Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer’s disease. Int Psychogeriatr. 2010, 22: 973-983. 10.1017/S1041610210000888.CrossRefPubMed Gauthier S, Lopez OL, Waldermar G, Jones RW, Cummings J, Zhang R, Schindler R, Schwam E: Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer’s disease. Int Psychogeriatr. 2010, 22: 973-983. 10.1017/S1041610210000888.CrossRefPubMed
3.
go back to reference Wimo A, Winblad B, Shah SN, Chin W, Zhang R, McRae T: Impact of donepezil treatment for Alzheimer’s disease on caregiver time. Curr Med Res Opin. 2004, 20: 1221-1225. 10.1185/030079902125004349.CrossRefPubMed Wimo A, Winblad B, Shah SN, Chin W, Zhang R, McRae T: Impact of donepezil treatment for Alzheimer’s disease on caregiver time. Curr Med Res Opin. 2004, 20: 1221-1225. 10.1185/030079902125004349.CrossRefPubMed
4.
go back to reference Hebert R, Dubois MF, Wolfson C, Chambers L, Cohen C: Factors associated with long-term institutionalization of older people with dementia: data from the Canadian study of health and aging. J Gerontol A Biol Sci Med Sci. 2001, 56: M693-M699. 10.1093/gerona/56.11.M693.CrossRefPubMed Hebert R, Dubois MF, Wolfson C, Chambers L, Cohen C: Factors associated with long-term institutionalization of older people with dementia: data from the Canadian study of health and aging. J Gerontol A Biol Sci Med Sci. 2001, 56: M693-M699. 10.1093/gerona/56.11.M693.CrossRefPubMed
5.
go back to reference Livingston G, Katona C, Francois C, Guilhaume C, Cochran J, Sapin C: Characteristics and health status change over 6 months in people with moderately severe to severe Alzheimer’s disease in the UK. Int Psychogeriatr. 2006, 18: 527-538. 10.1017/S1041610205002942.CrossRefPubMed Livingston G, Katona C, Francois C, Guilhaume C, Cochran J, Sapin C: Characteristics and health status change over 6 months in people with moderately severe to severe Alzheimer’s disease in the UK. Int Psychogeriatr. 2006, 18: 527-538. 10.1017/S1041610205002942.CrossRefPubMed
6.
go back to reference Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, Banerjee S, Lin P, Sano M: Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging. 2006, 10: 417-429.PubMed Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, Banerjee S, Lin P, Sano M: Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging. 2006, 10: 417-429.PubMed
7.
go back to reference Edvardsson D, Winblad B, Sandman PO: Person-centred care of people with severe Alzheimer’s disease: current status and ways forward. Lancet Neurol. 2008, 7: 362-367. 10.1016/S1474-4422(08)70063-2.CrossRefPubMed Edvardsson D, Winblad B, Sandman PO: Person-centred care of people with severe Alzheimer’s disease: current status and ways forward. Lancet Neurol. 2008, 7: 362-367. 10.1016/S1474-4422(08)70063-2.CrossRefPubMed
8.
go back to reference Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E: Donepezil MSAD Study Investigators Group: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2001, 57: 613-620. 10.1212/WNL.57.4.613.CrossRefPubMed Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E: Donepezil MSAD Study Investigators Group: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2001, 57: 613-620. 10.1212/WNL.57.4.613.CrossRefPubMed
9.
go back to reference Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001, 49: 1590-1599. 10.1111/j.1532-5415.2001.49266.x.CrossRefPubMed Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001, 49: 1590-1599. 10.1111/j.1532-5415.2001.49266.x.CrossRefPubMed
10.
go back to reference Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A, Severe Alzheimer’s Disease Study Group: Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006, 367: 1057-1065. 10.1016/S0140-6736(06)68350-5.CrossRefPubMed Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A, Severe Alzheimer’s Disease Study Group: Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006, 367: 1057-1065. 10.1016/S0140-6736(06)68350-5.CrossRefPubMed
11.
go back to reference Black SE, Doody R, Li H, McRae T, Jambor KM, Xu J, Sun Y, Perdomo CA, Richardson S: Donepezil preserves cognition and global function in patients with severe Alzheimer’s disease. Neurology. 2007, 69: 459-469. 10.1212/01.wnl.0000266627.96040.5a.CrossRefPubMed Black SE, Doody R, Li H, McRae T, Jambor KM, Xu J, Sun Y, Perdomo CA, Richardson S: Donepezil preserves cognition and global function in patients with severe Alzheimer’s disease. Neurology. 2007, 69: 459-469. 10.1212/01.wnl.0000266627.96040.5a.CrossRefPubMed
12.
go back to reference Jelic V, Haglund A, Kowalski J, Langworth S, WInbland B: Donepezil treatment of severe Alzheimer’s disease in nursing home settings: A responder analysis. Dement Geriatr Cogn Disord. 2008, 26: 458-466. 10.1159/000167267.CrossRefPubMed Jelic V, Haglund A, Kowalski J, Langworth S, WInbland B: Donepezil treatment of severe Alzheimer’s disease in nursing home settings: A responder analysis. Dement Geriatr Cogn Disord. 2008, 26: 458-466. 10.1159/000167267.CrossRefPubMed
13.
go back to reference Grasel E, Wiltfang J, Kornhuber J: Non-drug therapies for dementia: an overview of the current situation with regard to proof of effectiveness. Dement Geriatr Cogn Disord. 2003, 15: 115-125. 10.1159/000068477.CrossRefPubMed Grasel E, Wiltfang J, Kornhuber J: Non-drug therapies for dementia: an overview of the current situation with regard to proof of effectiveness. Dement Geriatr Cogn Disord. 2003, 15: 115-125. 10.1159/000068477.CrossRefPubMed
14.
go back to reference Zec RF: Neuropsychological Functioning in Alzheimer’s Disease. Neuropsychol Alzheimer’s Disease and Other Dementias. Edited by: Parks RW, Zec RF, Wilson RS. 1993, Oxford University Press, Oxford, 3-80. Zec RF: Neuropsychological Functioning in Alzheimer’s Disease. Neuropsychol Alzheimer’s Disease and Other Dementias. Edited by: Parks RW, Zec RF, Wilson RS. 1993, Oxford University Press, Oxford, 3-80.
15.
go back to reference Onder G, Zanetti O, Giacobini E, Frisoni GB, Bartorelli L, Carbone G, Lambertucci P, Silveri MC, Bernabei R: Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer’s disease: randomized controlled trial. Br J Psychiatr. 2005, 187: 450-455. 10.1192/bjp.187.5.450.CrossRef Onder G, Zanetti O, Giacobini E, Frisoni GB, Bartorelli L, Carbone G, Lambertucci P, Silveri MC, Bernabei R: Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer’s disease: randomized controlled trial. Br J Psychiatr. 2005, 187: 450-455. 10.1192/bjp.187.5.450.CrossRef
16.
go back to reference Spector A, Orrell M, Davies S, Woods B: Reality orientation for dementia. Cochrane Database Syst Rev 2007, (3):CD001119., Spector A, Orrell M, Davies S, Woods B: Reality orientation for dementia. Cochrane Database Syst Rev 2007, (3):CD001119.,
17.
go back to reference Woods B, Spector A, Jones C, Orrell M, Davies S: Reality orientation therapy for dementia. Cochrane Database Syst Rev 2005, (2):CD001120., Woods B, Spector A, Jones C, Orrell M, Davies S: Reality orientation therapy for dementia. Cochrane Database Syst Rev 2005, (2):CD001120.,
18.
go back to reference Meguro M, Kasai M, Akanuma K, Ishii H, Yamaguchi S, Meguro K: Comprehensive approach of donepezil and psychosocial intervention on cognitive function and quality of life for Alzheimer’s disease: the Osaki-Tajiri project. Age Ageing. 2008, 37: 469-473. 10.1093/ageing/afn107.CrossRefPubMed Meguro M, Kasai M, Akanuma K, Ishii H, Yamaguchi S, Meguro K: Comprehensive approach of donepezil and psychosocial intervention on cognitive function and quality of life for Alzheimer’s disease: the Osaki-Tajiri project. Age Ageing. 2008, 37: 469-473. 10.1093/ageing/afn107.CrossRefPubMed
19.
go back to reference Meguro K: Preventing withdrawal of cholinesterase inhibitors for Alzheimer’s patients: measures from three aspects. Psychogeriatrics 2014 [Epub]., Meguro K: Preventing withdrawal of cholinesterase inhibitors for Alzheimer’s patients: measures from three aspects. Psychogeriatrics 2014 [Epub].,
20.
go back to reference Umegaki H, Itoh A, Suzuki Y, Nabeshima T: Discontinuation of donepezil for the treatment of Alzheimer’s disease in geriatric practice. Int Psychogeriatr. 2008, 20 (4): 800-806.CrossRefPubMed Umegaki H, Itoh A, Suzuki Y, Nabeshima T: Discontinuation of donepezil for the treatment of Alzheimer’s disease in geriatric practice. Int Psychogeriatr. 2008, 20 (4): 800-806.CrossRefPubMed
21.
go back to reference Giordano M, Dominguez LJ, Vitrano T, Curatolo M, Ferlisi A, Prima AD, Belvedere M, Barbagallo M: Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer’s disease (AD). Arch Gerontol Geriatr. 2010, 52: 245-249. 10.1016/j.archger.2009.11.008.CrossRef Giordano M, Dominguez LJ, Vitrano T, Curatolo M, Ferlisi A, Prima AD, Belvedere M, Barbagallo M: Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer’s disease (AD). Arch Gerontol Geriatr. 2010, 52: 245-249. 10.1016/j.archger.2009.11.008.CrossRef
22.
go back to reference McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984, 34: 939-944. 10.1212/WNL.34.7.939.CrossRefPubMed McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984, 34: 939-944. 10.1212/WNL.34.7.939.CrossRefPubMed
23.
go back to reference Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.CrossRefPubMed Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.CrossRefPubMed
24.
go back to reference Toba K, Nakai R, Akishita M, Iijima S, Nishinaga M, Mizoguchi T: Vitality index as a useful tool to assess elderly with dementia. Geriatr Gerontol Int. 2002, 2: 23-29. 10.1046/j.1444-1586.2002.00016.x.CrossRef Toba K, Nakai R, Akishita M, Iijima S, Nishinaga M, Mizoguchi T: Vitality index as a useful tool to assess elderly with dementia. Geriatr Gerontol Int. 2002, 2: 23-29. 10.1046/j.1444-1586.2002.00016.x.CrossRef
25.
go back to reference Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, Pupi A, Robert PH, Rodriguez G, Darcourt J: Brain perfusion follow-up in Alzheimer’s patients during treatment with acetylcholinesterase inhibitors. J Nucl Med. 2002, 43: 983-990.PubMed Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, Pupi A, Robert PH, Rodriguez G, Darcourt J: Brain perfusion follow-up in Alzheimer’s patients during treatment with acetylcholinesterase inhibitors. J Nucl Med. 2002, 43: 983-990.PubMed
26.
go back to reference Nakano S, Asada T, Matsuda H, Uno M, Takasaki M: Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer’s disease. J Nucl Med. 2001, 42: 1441-1445.PubMed Nakano S, Asada T, Matsuda H, Uno M, Takasaki M: Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer’s disease. J Nucl Med. 2001, 42: 1441-1445.PubMed
27.
go back to reference Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatr. 2003, 11 (2): 169-177. 10.1097/00019442-200303000-00007.CrossRef Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatr. 2003, 11 (2): 169-177. 10.1097/00019442-200303000-00007.CrossRef
28.
go back to reference Panisset M, Roudier M, Saxton J, Boller F: Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol. 1994, 51: 41-45. 10.1001/archneur.1994.00540130067012.CrossRefPubMed Panisset M, Roudier M, Saxton J, Boller F: Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol. 1994, 51: 41-45. 10.1001/archneur.1994.00540130067012.CrossRefPubMed
Metadata
Title
Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer’s patients in long-term care health facilities
Authors
Kenichi Meguro
Yoshitaka Ouchi
Kyoko Akanuma
Mitsue Meguro
Mari Kasai
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-014-0243-7

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue